Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Fortress Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Product Name : Urece
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Fortress Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable